• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 


New Search Back to Search Results
Note: This medical device record is a PMA supplement. A supplement may have changed the device description/function or indication from that approved in the original PMA. Be sure to look at the original PMA record for more information.
 
DeviceFoundationOne CDx (F1CDx)
Generic Namenext generation sequencing oncology panel, somatic or germline variant detection system
Applicant
Foundation Medicine, Inc.
150 second street, 1st floor
cambridge, MA 02141
PMA NumberP170019
Supplement NumberS016
Date Received01/21/2020
Decision Date06/16/2020
Product Code PQP 
Docket Number 20M-1612
Notice Date 06/24/2020
Advisory Committee Pathology
Supplement Typepanel track
Supplement Reason labeling change - indications/instructions/shelf life/tradename
Expedited Review Granted? No
Combination Product No
Approval Order Statement 
Approval order to expand the intended use of FoundationOne®CDx (F1CDx) to include high tumor mutational burden (TMB) at the cut-off of greater than or equal to 10 mutations per megabase (mut/Mb) in patients with solid tumors who may benefit from treatment with KEYTRUDA® (pembrolizumab).
Approval Order Approval Order
Summary Summary of Safety and Effectiveness
Labeling Labeling
-
-